Cancer Family
Malignant Head and Neck Neoplasm
CI-CAN-00000236Explore in graph →
1,432 active trials17 approved drugs142 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000236Explore in graph →
Clinical trials
5,449 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (629)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05232851 | A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer | active not recruiting | Phase 1 / Phase 2 | 20 | Mayo ClinicOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT05576974 | A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY) | recruiting | Phase 2 | 120 | University of Texas Southwestern Medical Center |
| 1 |
| Apr 14, 2026 |
| clinicaltrials |
| NCT06093061 | Tislelizumab and Metronomic Capecitabine as Maintenance in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma | recruiting | Phase 2 | 53 | National Cancer Centre, SingaporeOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT07529873 | Phase II Study of Ficerafusp Alfa in Combination With Nivolumab in Patients With Platinum-refractory Head and Neck Squamous Cell Carcinoma(N'FORCE) | not yet recruiting | Phase 2 | 131 | Groupe Oncologie Radiotherapie Tete et CouOTHER | 0 | Apr 14, 2026 | clinicaltrials |
| NCT03323463 | Major De-escalation to 30 Gy for Select Human Papillomavirus Associated Oropharyngeal Carcinoma | active not recruiting | Phase 2 | 316 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT04061980 | Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer | active not recruiting | Phase 2 | 24 | Providence Health & ServicesOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT04620187 | Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas | recruiting | Phase 2 | 37 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05307939 | A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC) | recruiting | Phase 2 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06097468 | Nisin in Oral Cavity Squamous Cell Carcinoma (OCSCC) | recruiting | Phase 1 / Phase 2 | 40 | University of California, San FranciscoOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07423078 | Window of Opportunity in Preserving Laryngeal Function Trial(WOLF) | recruiting | Phase 2 | 87 | Matthew SpectorOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07496190 | Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy | recruiting | Phase 2 | 59 | Sun Yat-sen UniversityOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT04938609 | Neoadjuvant Immunoradiotherapy in Head & Neck Cancer (NIRT 2-HNC) | active not recruiting | Phase 2 | 28 | Providence Health & ServicesOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT05696548 | Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION) | active not recruiting | Phase 2 | 51 | National Cancer Center Hospital EastOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT06959108 | Clinical Trial Comparing Induction Treatment With EGFR-ADC MRG003 Alone or in Combination With the Anti PD1 Pucotenlimab, Followed by Radiochemotherapy in Locally Advanced Squamous Cell Cancers of the Head and Neck(IDEAL) | recruiting | Phase 2 | 106 | Groupe Oncologie Radiotherapie Tete et CouOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT07514767 | Evaluation of the Efficacy and Safety of Nivolumab Neoadjuvant Treatment of Patients With Locally Advanced Oral Squamous Cell Carcinoma(NOCANO) | not yet recruiting | Phase 2 | 60 | Prof. Lars Olaf CardellOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT03916627 | Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients | active not recruiting | Phase 2 | 65 | Regeneron PharmaceuticalsINDUSTRY | 1 | Apr 6, 2026 | clinicaltrials |
| NCT05924256 | A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing | active not recruiting | Phase 2 | 88 | Fudan UniversityOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT06145308 | Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing | recruiting | Phase 2 | 39 | Peking Union Medical CollegeOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT01898494 | Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer | active not recruiting | Phase 2 | 519 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Apr 1, 2026 | clinicaltrials |
| NCT05318027 | ChatBot and Activity Monitoring in Patients Undergoing Chemoradiotherapy | active not recruiting | Phase 2 | 70 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT05387915 | Biomarker-Driven Radiation Therapy Dose Reduction After Transoral Robotic Surgery for the Treatment of HPV-Positive Oropharyngeal Cancer | active not recruiting | Phase 2 | 33 | Emory UniversityOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT06137274 | Phase 2 Trial of Adaptive Radiotherapy Boost for HNSCC | recruiting | Phase 2 | 35 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT07464366 | The Safety and Efficacy of MRG003 With or Without Putrelimab in Recurrent or Metastatic Salivary Gland Cancer: a Single-center, Open-label Cohort Study(TSEMPRMSGC) | recruiting | Phase 2 | 90 | Ji DongmeiOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT05980000 | Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma(Rambro2) | active not recruiting | Phase 2 | 37 | Washington University School of MedicineOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT07247201 | Integrating Allogeneic NK Cells in High-risk Advanced Stage III-IV Nasopharyngeal Cancer Patients(AlloNK1) | not yet recruiting | Phase 1 / Phase 2 | 31 | Singapore General HospitalOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT07465276 | Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC | recruiting | Phase 2 | 32 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT03410615 | Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC | active not recruiting | Phase 2 | 129 | Canadian Cancer Trials GroupNETWORK | 4 | Mar 24, 2026 | clinicaltrials |
| NCT06323460 | Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer | recruiting | Phase 2 | 45 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Mar 24, 2026 | clinicaltrials |
| NCT07491783 | Nano-Carbon Iron Suspension Injection Combined With Radiotherapy for Solid Tumors Phase II Clinical Trial | not yet recruiting | Phase 2 | 52 | Sichuan Enray Pharmaceutical Sciences CompanyOTHER | 1 | Mar 24, 2026 | clinicaltrials |
| NCT07320963 | Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma. | not yet recruiting | Phase 1 / Phase 2 | 52 | Sun Yat-sen UniversityOTHER | 0 | Mar 20, 2026 | clinicaltrials |
| NCT07485296 | Effect of Postbiotics on Microbiota and Systemic Immunomodulation of Pembrolizumab as First-Line Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (RM HNSCC)(POST-BIO) | recruiting | Phase 2 | 45 | Gruppo Oncologico del Nord-OvestOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT06876038 | Low-cost Screening and Image-guided Photodynamic Therapy (PDT) of Premalignant and Malignant Oral Lesions | not yet recruiting | Phase 2 | 65 | University of Massachusetts, BostonOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT07092514 | Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC) | recruiting | Phase 2 | 34 | Washington University School of MedicineOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT07362979 | Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal Carcinoma | recruiting | Phase 2 | 243 | Sun Yat-sen UniversityOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT06332092 | FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma(HNSCC) | active not recruiting | Phase 2 | 46 | Fulgent Pharma LLC.INDUSTRY | 1 | Mar 16, 2026 | clinicaltrials |
| NCT03360890 | Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors(iPRIME) | active not recruiting | Phase 2 | 46 | University of ChicagoOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT06030440 | De-Intensification of Postoperative Radiotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck(DIREKHT2) | recruiting | Phase 2 / Phase 3 | 508 | University of Erlangen-Nürnberg Medical SchoolOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT07035249 | DCSZ11 in Combination With Standard Therapy in Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 9 | West China HospitalOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT04030455 | Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer | active not recruiting | Phase 2 | 28 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT07065630 | Response-Adaptive Treatment in Untreated Locoregional HPV-Negative Head and Neck Cancer | recruiting | Phase 2 | 38 | University of ChicagoOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT06208826 | A Single-center Phase II Study to Investigate the Immune Maintenance Therapy Pattern in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Who Have Achieved MPR After Neoadjuvant Immunotherapy Combined With Chemotherapy | recruiting | Phase 2 | 268 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07447050 | Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial | recruiting | Phase 2 | 24 | University of California, IrvineOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07447570 | Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC | recruiting | Phase 2 | 27 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07044635 | Shortened Course of Radiation Therapy After Trans-oral Robotic Surgery in Patients With HPV-Mediated Oropharyngeal Squamous Cell Carcinoma.(RAD RAPTORS) | recruiting | Phase 2 | 42 | University of UtahOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07193186 | Anlotinib and Benmelstobart in DTC | not yet recruiting | Phase 2 | 23 | Fudan UniversityOTHER | 0 | Feb 27, 2026 | clinicaltrials |
| NCT05261750 | Autologous Dendritic Cells and Allogenic Dendritic Secretomes for Patients With Advanced Nasopharyngeal Cancer | active not recruiting | Phase 1 / Phase 2 | 15 | PT. Prodia Stem Cell IndonesiaINDUSTRY | 1 | Feb 25, 2026 | clinicaltrials |
| NCT07433283 | Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor | recruiting | Phase 1 / Phase 2 | 54 | Sichuan Enray Pharmaceutical Sciences CompanyOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT03174275 | Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma | active not recruiting | Phase 2 | 39 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT07428148 | Lattice-Based Radiotherapy and Chemoimmunotherapy for Oropharyngeal Squamous Cell Carcinoma | not yet recruiting | Phase 1 / Phase 2 | 60 | NYU Langone HealthOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT04868877 | Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination | active not recruiting | Phase 1 / Phase 2 | 194 | Merus B.V.INDUSTRY | 9 | Feb 19, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Apr 14, 2026source: clinicaltrials